Chongqing Laimei Pharmaceutical

Chongqing Laimei Pharmaceutical is a prominent Chinese pharmaceutical company focused on the development, manufacturing, and commercialization of specialty medicines. The company is best known for its innovative Nanocarbon Suspension Injection, which serves as a vital lymphatic tracer in oncology surgeries for thyroid and breast cancers. Beyond its oncology portfolio, Laimei maintains a strong presence in gastroenterology with products like Esomeprazole Sodium and Rabeprazole Sodium. It also produces a range of anti-infectives, cardiovascular drugs, and immunomodulators such as Thymopentin. Listed on the Shenzhen Stock Exchange, the company has recently integrated state-owned capital to bolster its strategic growth and R&D initiatives. Laimei operates multiple GMP-certified manufacturing facilities and continues to expand its footprint in both domestic and international markets.